These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 29709248

  • 1. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression.
    Cillo U, Bechstein WO, Berlakovich G, Dutkowski P, Lehner F, Nadalin S, Saliba F, Schlitt HJ, Pratschke J.
    Transplant Rev (Orlando); 2018 Jul; 32(3):142-150. PubMed ID: 29709248
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Induction Therapy With ATG Compared With Anti-IL2 Basiliximab in Low-Immunologic Risk Kidney Transplant Recipients.
    Dedinská I, Graňák K, Vnučák M, Skálová P, Laca Ĺ, Krivuš J, Galajda P, Mokáň M.
    Transplant Proc; 2019 Dec; 51(10):3259-3264. PubMed ID: 31732198
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
    Pilch NA, Taber DJ, Moussa O, Thomas B, Denmark S, Meadows HB, McGillicuddy JW, Srinivas TR, Baliga PK, Chavin KD.
    Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial.
    Martinez-Mier G, Moreno-Ley PI, Budar-Fernández LF, Méndez-López MT, Allende-Castellanos CA, Jiménez-López LA, Barrera-Amoros DA, Aguilar-Sandoval E, De la Paz-Román M, Soto-Miranda E, Rivera-Sanchez Y, Martínez-Maldonado M.
    Transplant Proc; 2021 Apr; 53(3):1005-1009. PubMed ID: 32178925
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.
    Vincenti F, de Andrés A, Becker T, Choukroun G, Cole E, González-Posada JM, Kumar MA, Moore R, Nadalin S, Nashan B, Rostaing L, Saito K, Yoshimura N.
    Transpl Int; 2006 Jun; 19(6):446-57. PubMed ID: 16771865
    [Abstract] [Full Text] [Related]

  • 11. Antithymocyte Globulin Induction Therapy in Liver Transplant: Old Drug, New Uses.
    Petite SE, Bollinger JE, Eghtesad B.
    Ann Pharmacother; 2016 Jul; 50(7):592-8. PubMed ID: 27147705
    [Abstract] [Full Text] [Related]

  • 12. Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction.
    Lange NW, Salerno DM, Sammons CM, Jesudian AB, Verna EC, Brown RS.
    Clin Transplant; 2018 Dec; 32(12):e13415. PubMed ID: 30276862
    [Abstract] [Full Text] [Related]

  • 13. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S.
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.
    Peng W, Liu G, Xie W, Huang H, Wu J, Shou Z, Chen J.
    Int J Clin Pract Suppl; 2015 May; (183):23-8. PubMed ID: 26177071
    [Abstract] [Full Text] [Related]

  • 15. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR, Alnimri M, Weber-Shrikant E, Kohli R, Said M, Patel S, Pankewycz O.
    Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
    [Abstract] [Full Text] [Related]

  • 16. Induction Therapy With Antithymocyte Globulin and Delayed Calcineurin Inhibitor Initiation for Renal Protection in Liver Transplantation: A Multicenter Randomized Controlled Phase II-B Trial.
    Nair A, Coromina Hernandez L, Shah S, Zervos X, Zimmerman M, Sasaki K, Diago T, Hashimoto K, Fujiki M, Aucejo F, Bollinger J, Kaiser TL, Miller CM, Quintini C, Fung JJ, Eghtesad B.
    Transplantation; 2022 May 01; 106(5):997-1003. PubMed ID: 34319926
    [Abstract] [Full Text] [Related]

  • 17. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review.
    Nashan B.
    BioDrugs; 2005 May 01; 19(1):39-46. PubMed ID: 15691216
    [Abstract] [Full Text] [Related]

  • 18. A Single-Center Experience of the Optimal Initial Immunosuppressive Strategy for Preventing Early Acute Cellular Rejection in Orthotopic Heart Transplantation Associated With Renal Dysfunction.
    Mundisugih J, Fernando H, Bergin P, Hare J, Kaye D, Leet A, McGiffin D, Taylor AJ.
    Prog Transplant; 2019 Dec 01; 29(4):327-334. PubMed ID: 31476958
    [Abstract] [Full Text] [Related]

  • 19. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE, Enderby CY, Gonwa TA, Wadei HM.
    Clin Transplant; 2015 Jul 01; 29(7):573-80. PubMed ID: 25711849
    [Abstract] [Full Text] [Related]

  • 20. Antibody induction versus corticosteroid induction for liver transplant recipients.
    Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C.
    Cochrane Database Syst Rev; 2014 May 31; 2014(5):CD010252. PubMed ID: 24880007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.